Saturday 17 October 2026
Export CANF’s income statement to Excel — free account
Can-Fite Biopharma Ltd
CANF Healthcare Biotechnology
Can-Fite Biopharma Ltd’s revenue for fiscal 2025 (year ended December 2025) was $405,000.00, down 39.9% from fiscal 2024.
1.76
0.09
−4.86%
Follow CANF
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | 2 | 3 | 2 | 3 | 3 | 2 | 3 | 2 | 2 |
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
P/S ratio |
138.30 | 126.29 | 415.13 | 4.04 | 10,545.83 | 6,107.14 | 456.31 | 10.49 | 8.26 | 1.01 |
Altman Z-Score |
(11.22) | (13.93) | (15.77) | (21.94) | (18.54) | (8.32) | (23.32) | (22.40) | (25.57) | (27.99) |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(29.33) | (40.21) | (41.24) | (50.31) | (45.48) | (18.72) | (54.60) | (50.30) | (58.92) | (61.28) |
P/Operating CF |
(4.19) | (3.76) | (44.40) | (0.66) | (1,107.37) | (714.06) | (49.17) | (1.11) | (0.87) | (0.11) |
Beneish M-Score |
0.48 | 51.19 | (1.57) | 191.95 | (4.91) | — | — | — | — | — |
P/B ratio |
3.28 | 4.72 | 107.95 | 5.50 | 1,336.03 | 362.48 | 80.60 | 1.55 | 2.58 | 0.19 |
Price to Tangible BV |
3.28 | 4.72 | 107.95 | 5.50 | 1,336.03 | 362.48 | 80.60 | 1.55 | 2.58 | 0.19 |
EV/Sales |
70.59 | 81.55 | 410.17 | 1.73 | 10,534.99 | 6,084.72 | 446.20 | 0.25 | 2.16 | (7.31) |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.49 |
EV/Operating CF |
(0.93) | (1.06) | (19.15) | (0.12) | (361.54) | (280.89) | (15.54) | (0.01) | (0.09) | 0.28 |
EV/FCF |
(0.93) | (1.05) | (19.06) | (0.12) | (360.26) | (279.57) | (15.48) | (0.01) | (0.09) | 0.28 |
Quick Ratio |
4.04 | 3.80 | 2.53 | 2.18 | 7.41 | 7.01 | 3.19 | 4.42 | 3.84 | 3.13 |
Current Ratio |
4.04 | 3.80 | 2.53 | 2.18 | 7.41 | 7.35 | 3.66 | 4.91 | 4.38 | 3.46 |
Net Debt/EBITDA |
0.94 | 0.49 | 0.72 | 0.23 | 0.59 | 1.49 | 0.79 | 1.09 | 0.97 | 0.86 |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.01 | 0.09 | 0.49 | 0.25 | 0.09 | 0.06 | 0.05 | 0.08 | 0.07 | 0.04 |
Operating CF/Net income |
1.29 | 1.42 | 0.63 | 0.88 | 0.80 | 0.65 | 1.06 | 1.11 | 0.97 | 0.91 |
Capex/Depreciation |
(0.56) | (1.53) | (2.36) | (0.21) | (2.17) | (0.79) | (0.64) | (0.13) | (0.71) | (0.08) |
Interest Coverage |
(48.52) | (11.57) | (4.50) | (19.43) | (46.51) | 56.57 | (131.12) | — | — | — |
| (96.34%) | (142.61%) | (163.68%) | (462.71%) | (355.99%) | (148.66%) | (107.91%) | (142.49%) | (134.94%) | (178.24%) | |
| (49.68%) | (71.28%) | (84.43%) | (156.58%) | (171.31%) | (102.13%) | (68.89%) | (79.22%) | (82.47%) | (105.48%) | |
ROIC |
0.00% | (297.59%) | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(90.11%) | (128.37%) | (136.02%) | (322.97%) | (185.28%) | (87.46%) | (151.90%) | (96.43%) | (113.27%) | (146.38%) |
Average Days of Receivables |
4,279.09 | 1,461.39 | 383.63 | 787.30 | 505.64 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
3,577.06% | 647.15% | 159.03% | 540.16% | 1,566.32% | 1,154.75% | 958.40% | 805.25% | 854.15% | 1,652.59% |
Selling, General and Administrative Expense of Revenue |
1,603.53% | 363.50% | 82.70% | 150.74% | 386.76% | 450.76% | 388.02% | 397.71% | 452.08% | 904.20% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
179.41% | 24.33% | 14.01% | 18.95% | 46.53% | 54.63% | 32.47% | 35.13% | 53.71% | 83.95% |
Graham Net Nets |
0.30 | 0.21 | 0.01 | (0.03) | 0.00 | 0.00 | 0.01 | 0.63 | 0.37 | 5.20 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(21.00%) | (27.32%) | (11.63%) | (75.74%) | (40.46%) | (9.31%) | (15.26%) | (31.41%) | (39.89%) | (325.14%) |
Free Cash Flow Yield |
(54.95%) | (61.28%) | (5.18%) | (350.15%) | (0.28%) | (0.36%) | (6.32%) | (284.36%) | (291.06%) | (2,534.73%) |
Revenue per Share |
36.17 | 146.11 | 587.69 | 142.10 | 12.78 | 9.25 | 5.96 | 3.49 | 1.86 | 0.49 |
Operating CF per Share |
(1,900.21) | (1,661.48) | (639.23) | (775.10) | (202.06) | (106.92) | (79.42) | (39.61) | (21.06) | (10.87) |
Capex per Share |
(2.13) | (5.37) | (5.08) | (0.21) | (0.44) | (0.12) | (0.07) | (0.01) | (0.01) | 0.00 |
Free Cash Flow per Share |
(1,902.34) | (1,666.85) | (644.31) | (775.31) | (202.50) | (107.04) | (79.49) | (39.62) | (21.07) | (10.88) |
Cash per Share |
1,726.60 | 649.07 | 598.15 | 193.08 | 139.75 | 207.58 | 58.73 | 41.87 | 21.75 | 10.38 |
Shareholders Equity per Share |
824.68 | 928.52 | 463.85 | 170.77 | 101.74 | 155.99 | 32.88 | 29.30 | 14.99 | 6.79 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
824.68 | 928.52 | 463.85 | 170.77 | 101.74 | 155.99 | 32.88 | 29.30 | 14.99 | 6.79 |
Free Cash Flow |
(8.94) | (9.00) | (4.19) | (11.09) | (12.09) | (9.87) | (10.81) | (8.44) | (7.64) | (8.95) |
Working Capital |
7.60 | 4.91 | 4.78 | 3.87 | 8.13 | 17.34 | 6.66 | 7.89 | 6.93 | 6.71 |
Capital Expenditures |
(0.01) | (0.03) | (0.03) | 0.00 | (0.03) | (0.01) | (0.01) | 0.00 | 0.00 | 0.00 |
Net Current Asset Value |
3.81 | 4.06 | 2.97 | 1.41 | 5.95 | 14.20 | 4.35 | 6.16 | 5.30 | 5.52 |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.49 |
Capex to Sales |
0.06 | 0.04 | 0.01 | 0.00 | 0.03 | 0.01 | 0.01 | 0.00 | 0.01 | 0.00 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.34 | 0.68 | 0.30 | 0.39 | 0.24 | 0.30 | 0.33 | 0.52 | 0.26 | 4.80 |
Cash ROIC |
(74.56%) | (105.66%) | (60.67%) | (213.09%) | (83.85%) | (29.44%) | (86.76%) | (55.67%) | (57.36%) | (63.34%) |
Accounts Receivable Turnover |
0.13 | 0.31 | 1.07 | 0.48 | 0.28 | 1.54 | 17.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
1.31 | 2.58 | 3.59 | 4.20 | 2.72 | 0.55 | 0.05 | — | — | — |
Average Payables |
1.87 | 1.80 | 1.81 | 2.48 | 1.83 | 1.38 | 1.77 | 1.52 | 1.48 | 1.93 |
Average Assets |
13.89 | 8.89 | 7.78 | 8.06 | 8.85 | 14.89 | 14.77 | 9.64 | 9.55 | 9.32 |
Average Common Equity |
7.16 | 4.45 | 4.01 | 2.73 | 4.26 | 10.23 | 9.43 | 5.36 | 5.84 | 5.51 |
Columns are period end dates